The signal this week: price comparison is becoming harder—not because numbers are absent, but because more providers are mixing introductory rates, prepaid effective prices, memberships, medication charges, and new oral or injectable paths on the same page.
This is the launch edition of the GLP Access & Price Alert, a weekly desk report from GLP.directory. It will track ordinary recurring costs, access changes, and fine print. It will not tell readers which medication to take or treat an affiliate payout as evidence.
Price move to watch: starter versus ongoing
OrderlyMeds’ official pricing page displayed compounded GLP-1 injections at $149 per month and compounded GLP-1/GIP injections at $299 per month at our September 10 check. Starter programs can display lower effective monthly figures because several months are purchased together or use an introductory schedule. The directory uses the ongoing figure in its headline and puts the starter structure in the notes.
Found advertised some compounded GLP-1 plans from $99 a month while explaining that longer 3-, 6-, and 12-month plans can lower the monthly rate. This is precisely where “from” needs a term label. Readers should confirm the total charged today and renewal before comparing.
Access move to watch: more paths on one platform
Several large programs now present more than one route—brand-name, compounded, insurance navigation, direct pay, injectable, or oral—under a single consumer brand. Ro, WeightWatchers Clinic, Noom Med, and Found each package the decision differently.
The existence of a product on a page does not establish that it is appropriate, prescribed, covered, or available for a particular reader. Profiles now separate the medication path from payment and program fee so those claims do not collapse into one badge.
Fine print of the week: “medication included”
That phrase still leaves four questions: included only if prescribed? Which product and starting dose? Does a higher dose change price? Which pharmacy dispenses it? Direct Meds says medication, when prescribed, is included in its program cost and advertises no monthly membership. The profile records that structure without publishing a private affiliate rate or treating a proposed commercial relationship as approval.
Regulatory note
The FDA continues to distinguish FDA-approved drugs from compounded products. Its consumer warning page discusses quality, fraudulent labeling, shipping, dosing, and adverse-event concerns. GLP.directory labels every advertised compounded route as not FDA approved.
What we checked
This issue reviewed official pages from Direct Meds, Ro, WeightWatchers, Noom, OrderlyMeds, Found, OpenLoop, Bask Health, and the FDA on September 10, 2026. Prices and availability can change after publication. Send documented corrections to corrections@glp.directory.
Commercial disclosure: GLP.directory is researching partner programs, including Direct Meds and OrderlyMeds. No payout influenced this issue, and a public application or private discussion is not treated as an active endorsement.
This report is general information, not medical advice. A licensed clinician who knows your history should guide treatment, prescribing, dosing, and switching decisions. Compounded drugs are not FDA approved.